Ursodeoxycholic Acid (UDCA)

  • – First introduced as dissolution therapy of radiolucent Gall stone in 1970
  • – It occurs naturally in small quantities in human bile (<4%)
  • Mechanism of Action:
  • – Enhance hepatic secretion
  • – Inhibit toxic, endogenous bile salt
  • – Stabilize hepatocyte membrane against toxic bile salt
  • – Inhibit fibrosis and apoptosis
  • – Replacement of endogenous bile acid
  • UDCA in PBC:
  • – Dose: 13-15 mg/kg/day
  • – Rapid and long lasting improvement in liver biochemistry
  • – Decrease histologic activity of interface hepatitis, inflammation, cholestasis, bile duct paucity
  • – It significantly decrease development of esophageal varices, ascites, delays cirrhosis progression

Copyrights © 2020 Arefin | Gastroenterology | Developed by Chumbok IT